Dolutegravir in Patients with Raltegravir-Resistant HIV

VIKING (Cohorts I & II)
Dolutegravir in Patients with Raltegravir Resistance
VIKING Study (Cohorts I & II): Study Design

<table>
<thead>
<tr>
<th>Day 1</th>
<th>Day 11</th>
<th>Week 24</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Functional Monotherapy Phase</strong></td>
<td><strong>Continuation Phase</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Cohort I</strong>: Dolutegravir: 50 mg QD</td>
<td><strong>Cohort I</strong>: Dolutegravir: 50 mg QD + OBR</td>
<td></td>
</tr>
<tr>
<td><strong>Cohort II</strong>: Dolutegravir: 50 mg BID</td>
<td><strong>Cohort II</strong>: Dolutegravir: 50 mg BID + OBR</td>
<td></td>
</tr>
</tbody>
</table>

**Study Design: VIKING**

- **Background**: Single-arm, phase 2b trial evaluating efficacy of once daily or twice daily dolutegravir in patients with integrase resistance
- **Inclusion Criteria (n=51)**
  - Age $\geq$18 years
  - HIV RNA $>1,000$ copies/mL
  - Documented resistance $\geq$3 ARV classes, including integrase inhibitors
- **Treatment Arms**
  - Cohort I*: dolutegravir 50 mg once daily
  - Cohort II*: dolutegravir 50 mg twice daily

*Failing regimen continued during day 1-10, then replaced with OBR through week 24

Dolutegravir in Patients with Raltegravir Resistance
VIKING Study (Cohorts I & II): Results

Week 24 Virologic Response

Conclusion: “Dolutegravir 50 mg twice daily with an optimized background provided greater and more durable benefit than the once-daily regimen. These data are the first clinical demonstration of the activity of any integrase inhibitor in subjects with HIV-1 resistant to raltegravir.”

Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.